Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1987 1
1989 1
1999 1
2000 1
2003 1
2005 1
2008 3
2009 1
2010 1
2011 3
2012 3
2013 3
2014 3
2015 2
2016 3
2017 4
2018 9
2019 6
2020 9
2021 8
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

59 results
Results by year
Filters applied: . Clear all
Page 1
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance. Poeschel V, et al. Among authors: altmann b. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9. Lancet. 2019. PMID: 31868632 Clinical Trial.
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, Schmidt C, Ruebe C, Loeffler M, Pfreundschuh M, Rosenwald A, Glass B, Lenz G, Schmitz N; German high-grade lymphoma Study Group. Friedrichs B, et al. Among authors: altmann b. Br J Haematol. 2019 Mar;184(5):760-768. doi: 10.1111/bjh.15710. Epub 2018 Dec 5. Br J Haematol. 2019. PMID: 30520013 Clinical Trial.
Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group).
Zettl F, Ziepert M, Altmann B, Zeynalova S, Held G, Pöschel V, Hohloch K, Wulf GG, Glass B, Schmitz N, Loeffler M, Trümper L. Zettl F, et al. Among authors: altmann b. Ann Hematol. 2021 Apr;100(4):1031-1038. doi: 10.1007/s00277-020-04345-3. Epub 2020 Nov 26. Ann Hematol. 2021. PMID: 33242101 Free PMC article.
USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma.
Engel K, Rudelius M, Slawska J, Jacobs L, Ahangarian Abhari B, Altmann B, Kurutz J, Rathakrishnan A, Fernández-Sáiz V, Brunner A, Targosz BS, Loewecke F, Gloeckner CJ, Ueffing M, Fulda S, Pfreundschuh M, Trümper L, Klapper W, Keller U, Jost PJ, Rosenwald A, Peschel C, Bassermann F. Engel K, et al. Among authors: altmann b. EMBO Mol Med. 2016 Aug 1;8(8):851-62. doi: 10.15252/emmm.201506047. Print 2016 Aug. EMBO Mol Med. 2016. PMID: 27317434 Free PMC article.
Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group.
Hohloch K, Altmann B, Pfreundschuh M, Loeffler M, Schmitz N, Zettl F, Ziepert M, Trümper L. Hohloch K, et al. Among authors: altmann b. Br J Haematol. 2018 Jan;180(2):236-245. doi: 10.1111/bjh.15029. Epub 2017 Nov 28. Br J Haematol. 2018. PMID: 29193018
SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status.
Croci GA, Au-Yeung RKH, Reinke S, Staiger AM, Koch K, Oschlies I, Richter J, Poeschel V, Held G, Loeffler M, Trümper L, Rosenwald A, Ott G, Spang R, Altmann B, Ziepert M, Klapper W. Croci GA, et al. Among authors: altmann b. Ann Oncol. 2021 Nov;32(11):1400-1409. doi: 10.1016/j.annonc.2021.08.1991. Epub 2021 Aug 24. Ann Oncol. 2021. PMID: 34438040
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, Greil R, Tournilhac O, Relander T, Viardot A, Wilhelm M, Wilhelm C, Pezzutto A, Zijlstra JM, Neste EVD, Lugtenburg PJ, Doorduijn JK, Gelder MV, van Imhoff GW, Zettl F, Braulke F, Nickelsen M, Glass B, Rosenwald A, Gaulard P, Loeffler M, Pfreundschuh M, Schmitz N, Trümper L; ACT-2 study investigators. Wulf GG, et al. Among authors: altmann b. Leukemia. 2021 Jan;35(1):143-155. doi: 10.1038/s41375-020-0838-5. Epub 2020 May 7. Leukemia. 2021. PMID: 32382083 Clinical Trial.
59 results